Uncut Roux-en-Y reconstruction after distal gastrectomy for gastric cancer.

Zhaolun Cai, Mingchun Mu, Qin Ma, Chunyu Liu, Zhiyuan Jiang, Baike Liu, Gang Ji, Bo Zhang
Author Information
  1. Zhaolun Cai: Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
  2. Mingchun Mu: Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
  3. Qin Ma: Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
  4. Chunyu Liu: Department of Pharmacy, Evidence-based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
  5. Zhiyuan Jiang: Department of Plastic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  6. Baike Liu: Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
  7. Gang Ji: Department of Digestive Surgery, State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
  8. Bo Zhang: Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.

Abstract

BACKGROUND: Choosing an optimal reconstruction method is pivotal for patients with gastric cancer undergoing distal gastrectomy. The uncut Roux-en-Y reconstruction, a variant of the conventional Roux-en-Y approach (or variant of the Billroth II reconstruction), employs uncut devices to occlude the afferent loop of the jejunum. This modification is designed to mitigate postgastrectomy syndrome and enhance long-term functional outcomes. However, the comparative benefits and potential harms of this approach compared to other reconstruction techniques remain a topic of debate.
OBJECTIVES: To assess the benefits and harms of uncut Roux-en-Y reconstruction after distal gastrectomy in patients with gastric cancer.
SEARCH METHODS: We searched CENTRAL, PubMed, Embase, WanFang Data, China National Knowledge Infrastructure, and clinical trial registries for published and unpublished trials up to November 2023. We also manually reviewed references from relevant systematic reviews identified by our search. We did not impose any language restrictions.
SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi-RCTs comparing uncut Roux-en-Y reconstruction versus other reconstructions after distal gastrectomy for gastric cancer. The comparison groups encompassed other reconstructions such as Billroth I, Billroth II (with or without Braun anastomosis), and Roux-en-Y reconstruction.
DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures. The critical outcomes included health-related quality of life at least six months after surgery, major postoperative complications within 30 days after surgery according to the Clavien-Dindo Classification (grades III to V), anastomotic leakage within 30 days, changes in body weight (kg) at least six months after surgery, and incidence of bile reflux, remnant gastritis, and oesophagitis at least six months after surgery. We used the GRADE approach to evaluate the certainty of the evidence.
MAIN RESULTS: We identified eight trials, including 1167 participants, which contributed data to our meta-analyses. These trials were exclusively conducted in East Asian countries, predominantly in China. The studies varied in the types of uncut devices used, ranging from 2- to 6-row linear staplers to suture lines. The follow-up periods for long-term outcomes spanned from 3 months to 42 months, with most studies focusing on a 6- to 12-month range. We rated the certainty of evidence from low to very low. Uncut Roux-en-Y reconstruction versus Billroth II reconstruction In the realm of surgical complications, very low-certainty evidence suggests that uncut Roux-en-Y reconstruction compared with Billroth II reconstruction may make little to no difference to major postoperative complications (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.24 to 4.05; I² = 0%; risk difference (RD) 0.00, 95% CI -0.04 to 0.04; I² = 0%; 2 studies, 282 participants; very low-certainty evidence) and incidence of anastomotic leakage (RR 0.64, 95% CI 0.29 to 1.44; I² not applicable; RD -0.00, 95% CI -0.03 to 0.02; I² = 32%; 3 studies, 615 participants; very low-certainty evidence). We are very uncertain about these results. Focusing on long-term outcomes, low- to very low-certainty evidence suggests that uncut Roux-en-Y reconstruction compared with Billroth II reconstruction may make little to no difference to changes in body weight (mean difference (MD) 0.04 kg, 95% CI -0.84 to 0.92 kg; I² = 0%; 2 studies, 233 participants; low-certainty evidence), may reduce the incidence of bile reflux into the remnant stomach (RR 0.67, 95% CI 0.55 to 0.83; RD -0.29, 95% CI -0.43 to -0.16; number needed to treat for an additional beneficial outcome (NNTB) 4, 95% CI 3 to 7; 1 study, 141 participants; low-certainty evidence), and may have little or no effect on the incidence of remnant gastritis (RR 0.27, 95% CI 0.01 to 5.06; I = 78%; RD -0.15, 95% CI -0.23 to -0.07; I = 0%; NNTB 7, 95% CI 5 to 15; 2 studies, 265 participants; very low-certainty evidence). No studies reported on quality of life or the incidence of oesophagitis. Uncut Roux-en-Y reconstruction versus Roux-en-Y reconstruction In the realm of surgical complications, very low-certainty evidence suggests that uncut Roux-en-Y reconstruction compared with Roux-en-Y reconstruction may make little to no difference to major postoperative complications (RR 4.74, 95% CI 0.23 to 97.08; I² not applicable; RD 0.01, 95% CI -0.02 to 0.04; I² = 0%; 2 studies, 256 participants; very low-certainty evidence) and incidence of anastomotic leakage (RR 0.34, 95% CI 0.05 to 2.08; I² = 0%; RD -0.02, 95% CI -0.06 to 0.02; I² = 0%; 2 studies, 213 participants; very low-certainty evidence). We are very uncertain about these results. Focusing on long-term outcomes, very low-certainty evidence suggests that uncut Roux-en-Y reconstruction compared with Roux-en-Y reconstruction may increase the incidence of bile reflux into the remnant stomach (RR 10.74, 95% CI 3.52 to 32.76; RD 0.57, 95% CI 0.43 to 0.71; NNT for an additional harmful outcome (NNTH) 2, 95% CI 2 to 3; 1 study, 108 participants; very low-certainty evidence) and may make little to no difference to the incidence of remnant gastritis (RR 1.18, 95% CI 0.69 to 2.01; I² = 60%; RD 0.03, 95% CI -0.03 to 0.08; I² = 0%; 3 studies, 361 participants; very low-certainty evidence) and incidence of oesophagitis (RR 0.82, 95% CI 0.53 to 1.26; I² = 0%; RD -0.02, 95% CI -0.07 to 0.03; I² = 0%; 3 studies, 361 participants; very low-certainty evidence). We are very uncertain about these results. Data were insufficient to assess the impact on quality of life and changes in body weight.
AUTHORS' CONCLUSIONS: Given the predominance of low- to very low-certainty evidence, this Cochrane review faces challenges in providing definitive clinical guidance. We found the majority of critical outcomes may be comparable between the uncut Roux-en-Y reconstruction and other methods, but we are very uncertain about most of these results. Nevertheless, it indicates that uncut Roux-en-Y reconstruction may reduce the incidence of bile reflux compared to Billroth-II reconstruction, albeit with low certainty. In contrast, compared to Roux-en-Y reconstruction, uncut Roux-en-Y may increase bile reflux incidence, based on very low-certainty evidence. To strengthen the evidence base, further rigorous and long-term trials are needed. Additionally, these studies should explore variations in surgical procedures, particularly regarding uncut devices and methods to prevent recanalisation. Future research may potentially alter the conclusions of this review.

Associated Data

ClinicalTrials.gov | NCT02644148; NCT02694081; NCT03624725; NCT02763878; NCT03349398

References

  1. Medicine (Baltimore). 2019 Dec;98(51):e18381 [PMID: 31860999]
  2. Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1341-1347 [PMID: 27748146]
  3. J Gastric Cancer. 2014 Dec;14(4):229-37 [PMID: 25580354]
  4. BMC Surg. 2020 Jan 9;20(1):7 [PMID: 31918683]
  5. J Am Coll Surg. 2014 Jan;218(1):e17-21 [PMID: 24280449]
  6. BMJ. 2008 Mar 15;336(7644):601-5 [PMID: 18316340]
  7. BMJ. 2021 Mar 29;372:n160 [PMID: 33781993]
  8. Cochrane Database Syst Rev. 2024 Feb 29;2:CD015014 [PMID: 38421211]
  9. Int J Surg. 2022 Jan;97:106184 [PMID: 34861427]
  10. Nat Rev Endocrinol. 2020 Aug;16(8):448-466 [PMID: 32457534]
  11. Am J Surg. 1990 Sep;160(3):252-6 [PMID: 2393051]
  12. Int J Surg. 2022 Aug;104:106773 [PMID: 35863623]
  13. Cochrane Database Syst Rev. 2022 Nov 24;11:ED000160 [PMID: 36421032]
  14. Gastric Cancer. 2018 Nov;21(6):1031-1040 [PMID: 29728791]
  15. J Gastroenterol. 2022 Apr;57(4):267-285 [PMID: 35226174]
  16. World J Gastrointest Oncol. 2022 Jun 15;14(6):1141-1147 [PMID: 35949212]
  17. Br J Surg. 2021 Jun 24;: [PMID: 34165555]
  18. Ann Surg. 2018 Feb;267(2):236-242 [PMID: 28383294]
  19. Cochrane Database Syst Rev. 2007 Apr 18;(2):MR000010 [PMID: 17443631]
  20. World J Gastroenterol. 2018 Jun 28;24(24):2628-2639 [PMID: 29962819]
  21. Cancer Manag Res. 2019 Feb 19;11:1697-1704 [PMID: 30863178]
  22. BMJ. 2010 Mar 23;340:c332 [PMID: 20332509]
  23. Br J Surg. 1999 Feb;86(2):271-5 [PMID: 10100802]
  24. Surg Oncol. 2018 Sep;27(3):563-574 [PMID: 30217320]
  25. Cochrane Database Syst Rev. 2021 Sep 15;9:CD012998 [PMID: 34523717]
  26. World J Gastroenterol. 2016 Jan 21;22(3):1101-13 [PMID: 26811650]
  27. Gastric Cancer. 2023 Jan;26(1):1-25 [PMID: 36342574]
  28. Am J Surg. 2000 Jul;180(1):37-40 [PMID: 11036137]
  29. Surg Gynecol Obstet. 1988 Jan;166(1):69-70 [PMID: 3336817]
  30. Am J Surg. 1995 Oct;170(4):381-6 [PMID: 7573733]
  31. Gastric Cancer. 2005;8(4):253-7 [PMID: 16328601]
  32. Gut. 1999 Aug;45(2):172-80 [PMID: 10403727]
  33. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  34. World J Surg. 2018 Dec;42(12):4022-4032 [PMID: 29915987]
  35. Health Info Libr J. 2019 Sep;36(3):264-277 [PMID: 31328866]
  36. World J Gastrointest Surg. 2022 Jun 27;14(6):594-610 [PMID: 35979420]
  37. Gastric Cancer. 2002;5(2):83-9 [PMID: 12111583]
  38. Cancer Control. 2022 Jan-Dec;29:10732748221087059 [PMID: 35412845]
  39. Surg Endosc. 2023 Aug;37(8):6172-6184 [PMID: 37160808]
  40. Indian J Surg. 2010 Jun;72(3):236-9 [PMID: 23133254]
  41. J Clin Epidemiol. 2020 Mar;119:126-135 [PMID: 31711912]
  42. Pol Merkur Lekarski. 1998 Apr;4(22):190-2 [PMID: 9770993]
  43. Arch Surg. 1992 Mar;127(3):295-300 [PMID: 1489374]
  44. Ann Gastroenterol Surg. 2020 Feb 04;4(2):142-150 [PMID: 32258979]
  45. BMJ Open. 2018 Oct 17;8(10):e021796 [PMID: 30337308]
  46. Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Feb 25;25(2):166-172 [PMID: 35176829]
  47. BMJ Open. 2020 Feb 12;10(2):e034782 [PMID: 32051319]
  48. BMJ. 1997 Sep 13;315(7109):629-34 [PMID: 9310563]
  49. J Gastric Cancer. 2022 Apr;22(2):83-93 [PMID: 35534446]
  50. Ann Surg. 2004 Aug;240(2):205-13 [PMID: 15273542]
  51. Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Jul 25;23(7):717-719 [PMID: 32683835]
  52. World J Gastroenterol. 2017 Sep 14;23(34):6350-6356 [PMID: 28974902]
  53. J Dig Dis. 2021 Jul;22(7):376-389 [PMID: 34105263]
  54. BMJ. 2019 Aug 28;366:l4898 [PMID: 31462531]
  55. Trials. 2019 Jul 12;20(1):428 [PMID: 31300019]
  56. Medicine (Baltimore). 2018 May;97(20):e10823 [PMID: 29768387]
  57. Chin Med J (Engl). 2022 Feb 9;135(5):584-590 [PMID: 35143424]
  58. Langenbecks Arch Surg. 2022 Feb;407(1):75-86 [PMID: 35094151]
  59. Front Surg. 2021 Aug 06;8:644864 [PMID: 34422889]
  60. Surg Endosc. 2022 Oct;36(10):7588-7596 [PMID: 35380283]
  61. Cochrane Database Syst Rev. 2024 Jan 16;1:CD015213 [PMID: 38226663]
  62. Ann Surg Oncol. 2021 Jan;28(1):90-96 [PMID: 32556870]
  63. Cancer Commun (Lond). 2021 Aug;41(8):747-795 [PMID: 34197702]
  64. BMJ. 2020 Jan 16;368:l6890 [PMID: 31948937]
  65. J Gastrointest Surg. 2023 Jun;27(6):1098-1105 [PMID: 36917403]

MeSH Term

Humans
Stomach Neoplasms
Gastrectomy
Randomized Controlled Trials as Topic
Anastomosis, Roux-en-Y
Quality of Life
Gastroenterostomy
Postoperative Complications
Jejunum
Postgastrectomy Syndromes
Bias

Word Cloud

Created with Highcharts 10.0.00reconstruction95%CIRoux-en-Yevidencelow-certainty-0uncut=studiesincidenceparticipantsmay0%RRRD2compared3BillrothoutcomesdifferenceIIlong-termtrialsmonthscomplicationsbilerefluxremnantlittle102gastriccancerdistalgastrectomysurgerysuggestsmake0403uncertainresultsapproachdevicesversususedqualitylifeleastsixmajorpostoperativeanastomoticleakagechangesbodyweightkggastritisoesophagitiscertaintylowUncutsurgical40108patientsvariantbenefitsharmsassessDataChinaclinicalidentifiedincludedreconstructionsCochraneprocedurescriticalwithin30daysrealmrisk050029applicableFocusinglow-reducestomach43neededadditionaloutcomeNNTB7study50615230774increase361reviewmethodsBACKGROUND:ChoosingoptimalmethodpivotalundergoingconventionalemploysoccludeafferentloopjejunummodificationdesignedmitigatepostgastrectomysyndromeenhancefunctionalHowevercomparativepotentialtechniquesremaintopicdebateOBJECTIVES:SEARCHMETHODS:searchedCENTRALPubMedEmbaseWanFangNationalKnowledgeInfrastructuretrialregistriespublishedunpublishedNovember2023alsomanuallyreviewedreferencesrelevantsystematicreviewssearchimposelanguagerestrictionsSELECTIONCRITERIA:randomisedcontrolledRCTsquasi-RCTscomparingcomparisongroupsencompassedwithoutBraunanastomosisDATACOLLECTIONANDANALYSIS:standardmethodologicalhealth-relatedaccordingClavien-DindoClassificationgradesIIIVGRADEevaluateMAINRESULTS:eightincluding1167contributeddatameta-analysesexclusivelyconductedEastAsiancountriespredominantlyvariedtypesranging2-6-rowlinearstaplerssuturelinesfollow-upperiodsspanned42focusing6-12-monthrangeratedratio98confidenceinterval24282644432%615meanMD849223367558316numbertreatbeneficial141effect2778%265reported9725634213105232765771NNTharmfulNNTH108186960%825326insufficientimpactAUTHORS'CONCLUSIONS:GivenpredominancefaceschallengesprovidingdefinitiveguidancefoundmajoritycomparableNeverthelessindicatesBillroth-IIalbeitcontrastbasedstrengthenbaserigorousAdditionallyexplorevariationsparticularlyregardingpreventrecanalisationFutureresearchpotentiallyalterconclusions

Similar Articles

Cited By